Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Internal Medicine
•
Hematology
Do you use lenalidomide for patients with MDS with 5q- without other cytogenetic abnormalities but with one or more mutations on NGS?
Are there certain mutations that would lead you to avoid use of lenalidomide, for example TP53?
Related Questions
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
Is there an advantage to early therapy with hypomethylating agents for high/very high risk patients with MDS who are not transplant candidates and have only mild cytopenias?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
How do you approach management for CCUS with severe cytopenias?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
Would you consider replacing ibrutinib with acalabrutinib or zanubrutinib in the TRIANGLE regimen for MCL in a patient with atrial fibrillation or high risk coronary syndromes who is otherwise fit for aggressive induction therapy?